Biolin Scientific Holding AB has appointed Thais T. Johansen as VP of the Drug Discovery business unit (Sophion), where he replaces Morten Sunesen.
Thais brings more than 20 years of commercial experience within the life science and medical device industries and a proven track record of leading teams to drive innovation and revenue growth. He has lived and worked internationally for more than 15 years. Thais joins Biolin Scientific from AdvanDx, Inc. where he held the position as CEO. Prior to this, Thais has been working for Vicare Medical, Boston Scientific, Polaroid Corporation and Boston Probes.
Morten have decided to pursue an opportunity as CEO for a Danish company, also in life science. Morten will work in parallel to Thais until 1 August to ensure a smooth transition.
Commenting on this announcement, Johan von Heijne, CEO of Biolin Scientific said
“Although we are sad that Morten has chosen to leave Biolin Scientific, we are thankful for the tremendous work Morten has put into Sophion in the past eleven years” and continued “We are pleased to welcome Thais in the Biolin family and believe that he with his vast experience in life science and diagnostics will support our ambition to help our customers deliver more and better drugs, faster."
Biolin Scientific is a leading Nordic instrumentation company with roots in Sweden, Denmark and Finland. Our customers include companies working with pharmaceuticals, energy, chemicals, and advanced materials, as well as academic and governmental research institutes. Our precision instruments help discover better drugs faster, develop better solutions for energy and materials, and perform research at the frontiers of science and technology.
Our commitment to customer service and application support is a key feature of our operations. We focus on working together with customers and building long-standing relations. Today, Biolin Scientific provides products and services in more than 70 countries around the world.